Adamis Pharmaceuticals (ADMP) Announces Proposed Common Share Offering

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Raymond James & Associates, Inc. will act as the sole book-running manager for the proposed offering.

The company intends to use the net proceeds from this offering for general corporate purposes, which may include, without limitation, expenditures relating to research, development and clinical trials relating to its products and product candidates, capital expenditures, manufacturing, hiring additional personnel, acquisitions of new technologies or products, the payment, repayment, refinancing, redemption or repurchase of existing or future indebtedness, obligations or capital stock, and working capital.

You May Also Be Interested In

• CervoMed closes $10M stock offering at $4.00 per share
• BuzzFeed sells shares to Byron Allen affiliate for $5.8 million
• MacroGenics to receive $24.5M milestone from Sanofi on FDA approval